The costs of treatment resistant depression: evidence from a survey among Italian patients

References

• Murray CJ. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012 Dec 15;380(9859):2197–2223.
   PubMed Web of Science ®Google Scholar
• Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the global burden of disease study 2010. Lancet. 2013 Nov 9;382(9904):1575–1586. Epub 2013 Aug 29. PMID: 23993280.
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, Bruffaerts R, Posada- Villa J, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA. 2004;291(21):2581–2590.
   PubMed Web of Science ®Google Scholar
• Epidemiology of Mental Disorders (ESEMeD) Project. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004; (420): 21–27.
   PubMedGoogle Scholar
• Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health. 2013;341:119–138. PMID: 23514317; PMCID: PMC4100461
   PubMed Web of Science ®Google Scholar
• Amos TB, Tandon N, Lefebvre P, et al. Direct and indirect cost burden and change of employment status in treatment-resistant depression: a matched-cohort study using a US commercial claims database. J Clin Psychiatry. 2018 Mar/Apr;79(2):17m11725. PMID: 29474009.
   PubMed Web of Science ®Google Scholar
• Krauth C, Stahmeyer JT, Petersen JJ, et al. Resource utilisation and costs of depressive patients in Germany: results from the primary care monitoring for depressive patients trial. Depress Res Treat. 2014;2014:730891. Epub 2014 Sep 9. PMID: 25295184; PMCID: PMC4175396.
   PubMedGoogle Scholar
• Binkin N, Gigantesco A, Ferrante G. Depressive symptoms among adults 18-69 years in Italy: results from the Italian behavioural risk factor surveillance system, 2007. Int J Public Health. 2010 Oct;55(5):479–488.
   PubMed Web of Science ®Google Scholar
• Conti DJ, Burton WN. The economic impact of depression in a workplace. J Occup Med. 1994.
   PubMedGoogle Scholar
• Beeler I, Lorenz S, Szucs TD. Provision and remuneration of psychotherapeutic services in Switzerland. Sozial und Praventivmedizin. 2003;48(2):88–96.
   PubMedGoogle Scholar
• Tomonaga Y, Haettenschwiler J, Hatzinger M, et al. The economic burden of depression in Switzerland. Pharmacoeconomics. 2013 Mar;31(3):237–250. PMID: 23417609.
   PubMed Web of Science ®Google Scholar
• Kleine-Budde K, Müller R, Kawohl W, et al. The cost of depression - a cost analysis from a large database. J Affect Disord. 2013 May;147(1–3):137–143. Epub 2012 Nov 17.
   PubMed Web of Science ®Google Scholar
• Agenzia Italiana del Farmaco (AIFA). Guideline for the classification and conduction of the observational studies on medicines. [Internet]. 2010.
   Google Scholar
• Carta MG, Aguglia E, Bocchetta A, et al. The use of antidepressant drugs and the lifetime prevalence of major depressive disorders in Italy. Clin Pract Epidemiol Ment Health. 2010;6(1): 94–100.
   PubMedGoogle Scholar
• Wittcampf KA, Naeije L, Schene AH, et al. Diagnostic accuracy of the mood module of the patient health questionnaire: a systematic review. Gen Hosp Psychiatry. 2007;29(5): 388–395.
   PubMed Web of Science ®Google Scholar
• Ventriglio A, Bhugra D, Sampogna G, et al. From dysthymia to treatment-resistant depression: evolution of a psychopathological construct. Int Rev Psychiatry. 2020;32(5–6):471–476.
   PubMed Web of Science ®Google Scholar
• De Berardis D, Fornaro M, Anastasia A, et al. Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a “real-world” chart review study. Braz J Psychiatry Internet]. 2020 June cited. 2021 May;42(3):317–321.
   PubMed Web of Science ®Google Scholar
• Serafini G, Adavastro G, Canepa G, et al. Abnormalities in kynurenine pathway metabolism in treatment-resistant depression and suicidality: A systematic review. CNS Neurol Disord Drug Targets. 2017;16(4):440–453.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Hesser JE. A comparison of depression and mental distress indicators, Rhode Island behavioral risk factor surveillance system, 2006. Prev Chronic Dis. 2011;8(2):A37.
   PubMed Web of Science ®Google Scholar
• Perrone V, Sangiorgi D, Andretta M, et al. Assessment of patients affected by treatment-resistant depression: Findings from a real-world study in Italy. J Psychiatry Psychiatr Disord. 2020;4:104–117.
   Google Scholar
• Ruggeri M, Drago C, Cadeddu C, et al. The determinants of out-of-pocket expenditure in ibd italian patients. results from the AMICI Survey. Int J Environ Res Public Health. 2020;17(21):8156.
   Web of Science ®Google Scholar
• Jaffe DH, Rive B, Denee TR. The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study. BMC Psychiatry. 2019 Aug 7;19(1):247.
   PubMed Web of Science ®Google Scholar
• Fornaro M, Giosuè P. Current nosology of treatment resistant depression: a controversy resistant to revision. Clin Pract Epidemiol Ment Health. 2010 May;4(6):20–24.
   Google Scholar
• Fornaro M, De Berardis D, Anastasia A, et al. Novel psychopharmacology for depressive disorders. Adv Exp Med Biol. 2021;1305:449–461.
   PubMed Web of Science ®Google Scholar
• Ruggeri M, Drago C, Moramarco V, et al. MUNROS team. New professional roles and patient satisfaction: evidence from a European survey along three clinical pathways. Health Policy. 2018 Oct;122(10):1078–1084. Epub 2018 Aug 1. PMID: 30227975.
   PubMed Web of Science ®Google Scholar